Can Metformin Extend Survival in Breast Cancer Patients?

Research published in The Oncologist found that Metformin, used in breast cancer patients with diabetes, extended overall and cancer-related survival.
The diabetes drug Metformin has an interesting discovery story: used for flu treatment in the 1950s, it was observed to lower blood sugar and first entered diabetes use in 1957. Synthesized from an extract of Galega officinalis, it reduces liver glucose production and consequently increases insulin sensitivity. It is used in prediabetic insulin resistance, type-2 diabetes, nonalcoholic fatty liver and polycystic ovary syndrome. It is also being studied in certain cancers, particularly breast cancer.
Citing evidence for Metformin’s anticancer nature, researchers stated that this investigation was inevitable. Another study also specifically focused on Metformin in breast cancer patients with or without diabetes.
The multidisciplinary team, including oncologists and epidemiologists, searched the literature from 10 January 2015 onward in databases [PubMed, Embase, Web of Science (Thomson Scientific), China Knowledge Resource Integrated Database, VIP Journal Integration Platform, Chinese Biomedical Literature databases].
The study searched articles examining the relationship between Metformin use and outcomes in breast cancer patients. Use was assessed as “already using at cancer diagnosis or starting at diagnosis” or “starting after cancer diagnosis.”
The research examined 234 abstracts and, from 2751 titles, 65 articles. Based on criteria, 11 articles were included. These contained information on 5464 patients with both breast cancer and diabetes. Of these, 2760 received Metformin and 2704 did not.
Average patient numbers in each study were 141. Survival was calculated from cancer diagnosis or, in surgical groups, from surgery. Diabetes was identified from blood tests and/or medical records.
All-Cause Mortality, Cancer Mortality and Metformin
The study showed a 47% reduction in all-cause mortality risk in breast cancer patients using Metformin for diabetes. After determining hormone receptor expression in malignant tissue (hormone-positive breast cancer), Metformin use was also found to greatly reduce mortality risk (65%).
Comparing Cancer Patients With and Without Diabetes
Compared with cancer patients without diabetes, breast cancer patients with diabetes using Metformin had significantly reduced all-cause mortality risk. The article stated that patients with severe diabetes receive milder cancer treatments because diabetes’ metabolic consequences would adversely affect treatment response. Analyses observed a positive survival contribution of Metformin in breast cancer patients with diabetes compared with those without diabetes.
The strength of the study is the large number of patients examined. However, further studies are needed to confirm Metformin use as a prognostic factor and the validity of incorporating antidiabetic drug concepts into breast cancer treatment.
Sources
Metformin use is associated with better survival of breast cancer patients with diabetes: a meta-analysis.
Oncologist.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.